title: Cardiovascular toxicity of anti-angiogenic drugs.
abstract: Anti-angiogenic targeted therapies are now major tools in the management of solid tumors. Briefly, one can distinguish between monoclonal antibodies such as bevacizumab directed against vascular endothelial growth factor (VEGF) and small molecules such as those targeted against receptors with tyrosine-kinase activity. Soon after they were marketed, these drugs showed cardiovascular toxicities, such as hypertension, left ventricular systolic dysfunction, heart failure and conduction abnormalities. The most frequent cardiovascular side effect of targeted therapies is hypertension, but the most life-threatening is QT prolongation with its risk of torsade de pointe and sudden cardiac death. Since the incidence of different types of cardiovascular side effects following targeted therapies varies across studies-and despite the fact that several meta-analyses attempted to summarize available information-those side effects are still not well identified. In addition, their reversibility is not precisely known. This review aims to present and discuss the various cardiovascular toxicities of anti-angiogenic targeted therapies for cancer.
authors: Department of Medical Oncology, France and Paris-XIII University, Bobighy. gdesguetz@gmail.com
authors: Gaetan
authors: G
authors: des Guetz
authors: Bernard
authors: B
authors: Uzzan
authors: Kader
authors: K
authors: Chouahnia
authors: Jean-François
authors: JF
authors: Morère
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006331:Heart Diseases / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans
chemical_list: D020533:Angiogenesis Inhibitors